Andrew Salib

Mr. Andrew Salib

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ASAndrew Salib
Andrew Salib
FCFritz Cayabyab
Fritz Cayabyab
EYEiji Yoshihara
Eiji Yoshihara
Since the discovery of insulin a century ago, insulin injection has been a primary treatment for both type 1 (T1D) and type 2 diabetes (T2D). T2D is a complicated disea se that is triggered by the dysfunction of insulin-producing β cells and insulin resistance in peripheral tissues. Insulin injection partially compensates for the role of endogenous insulin which promotes glucose uptake, lipid synthesis and organ growth. However, lacking the continuous, rapid, and accurate glucose regulation by endogenous functional β cells, the current insulin injection therapy is unable to treat the root causes of the disease. Thus, new technologies such as human pluripotent stem cell (hPSC)-derived islets are needed for both identifying the key molecular and genetic causes of T2D and for achieving a long-term treatment. This perspective review will provide insight into the efficacy of hPSC-derived human islets for treating and understanding T2D. We discuss the evidence that β cells should be the primary target for T2D treatment, the use of stem cells for the modeling of T2D and the potential use of hPSC-derived islet transplantation for treating T2D.

18 February 2026 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
VKVictoria Kong
Victoria Kong
ASAndrew Salib
Andrew Salib
JSJoshua Sanchez
Joshua Sanchez
OAOmar Allam
Omar Allam
MKMartin Kauke-Navarro
Martin Kauke-Navarro
MAMichael Alperovich
Michael Alperovich

24 February 2024 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
ASAndrew Salib
Andrew Salib
APAna L. Melero Pardo
Ana L. Melero Pardo
MLMichael Z. Lerner
Michael Z. Lerner

1 June 2026 in Journal of Hand Surgery Global Online
Verified
Journal Article
Open access
ASAndrew Salib
Andrew Salib
JSJoshua G. Sanchez
Joshua G. Sanchez
FDFortunay Diatta
Fortunay Diatta
KZKatie M. Zehner
Katie M. Zehner
VKVictoria Kong
Victoria Kong
DCDavid Colen
David Colen
This study compared postoperative complications and revision rates following endoscopic versus open carpal tunnel release (CTR) in obese and nonobese patients. A 2010–2022 national administrative database was queried to identify adults undergoing open or endoscopic CTR. Patients undergoing open and endoscopic CTR were each matched 1:1 for age, sex, diabetes, tobacco use, and Elixhauser Comorbidity Index in both the obese (body mass index > 30 kg/m2) and nonobese cohorts. Ninety-day complications and ipsilateral revision surgery within 5 years were compared using univariable and multivariable analysis for each cohort. In the obese matched cohort, endoscopic CTR was associated with lower rates of surgical site infection (0.46% vs 0.73%) and wound dehiscence (0.39% vs 0.72%) compared with open CTR (all P < .001). There was no significant difference in revision rates between endoscopic and open CTR (1.92% vs 2.01%, P = .466). On multivariable analysis, these associations remained significant (surgical site infection OR 0.62, 95% confidence interval [CI] 0.49–0.76 and wound dehiscence OR 0.53, 95% CI 0.42–0.67, all P < .001). In the nonobese cohort, endoscopic CTR was similarly associated with reduced rates of surgical site infection (0.30% vs 0.48%) and wound dehiscence (0.19% vs 0.40%) with corresponding reduced odds of surgical site infection (OR 0.64, 95% CI 0.59–0.70) and wound dehiscence (OR 0.47, 95% CI 0.43–0.52) (all P < .001). Revision rates were slightly higher in endoscopic versus open CTR (1.49% vs 1.39%, P = .007) for nonobese patients. There were no differences in hematoma or median nerve injuries in either cohort. Endoscopic CTR was associated with a decrease in wound complications in both obese and nonobese patients. There were comparable rates of revision surgery and median nerve injuries between the 2 surgical approaches. However, the clinical differences were modest, and the choice of surgical approach may remain at the discretion of the treating surgeon. Therapeutic IIb (Oxford CEBM Level 2b. Retrospective comparative cohort study)

Verified
Journal Article
Open access
PDF file
AKAlexander Kammien
Alexander Kammien
ASAndrew Salib
Andrew Salib
APAdnan Prsic
Adnan Prsic
JGJonathan N Grauer
Jonathan N Grauer
DCDaviid L Colen
Daviid L Colen
Background/Objectives: This national database study compares wide-awake hand surgeries in the United States performed in the operating room and office in terms of volume, reimbursement, narcotics prescriptions, and adverse events. Methods: Patients who underwent trigger finger release, open carpal tunnel release, De Quervain’s release, and mucous cyst excision from 2010 to 2022 were identified in PearlDiver’s M170Ortho dataset. Exclusion criteria were concomitant hand surgery, inpatient setting, <30 days of follow-up, age < 18 years, general/monitored anesthesia, and nerve block. Cohorts were stratified by surgical setting then matched by age, sex, Elixhauser Comorbidity Index score, and region. Primary endpoints included total and physician reimbursement (stratified by payor: commercial, Medicaid, Medicare) and 90-day narcotic prescriptions, emergency department visits, and surgical site infections. Results: Between 2010 and 2022, all surgical cohorts demonstrated an increase in the annual proportion of surgeries performed in the office (trigger finger +36%, carpal tunnel +155%, De Quervain’s +104%, mucous cyst +22%). Office-based surgery demonstrated lower total costs for all surgical cohorts and insurance types: commercial (−34% to −43%), Medicaid (−37% to −48%), Medicare (−30% to −37%). Office-based surgery had lower physician reimbursement for all surgical cohorts with commercial insurance (−3% to −9%) and Medicare (−5% to −13%). Physician reimbursement was not significantly different by surgical setting for Medicaid patients. Following office-based surgery, patients filled fewer narcotic prescriptions and had lower rates of emergency department visits, with similar rates of surgical site infection. Conclusions: Although most wide-awake hand surgeries are still performed in the operating room, there is a nationwide increase in office-based surgery. With reduced financial burden and favorable rates of adverse events, office-based wide-awake hand surgery may offer improved economic value and comparable short-term safety for certain procedures. Future research should complement these findings with patient-reported outcomes.

25 August 2026 in Journal of Craniofacial Surgery
Verified
Journal Article
Closed access
ASAndrew Salib
Andrew Salib
SGSamira Glaeser-Khan
Samira Glaeser-Khan
VKVictoria Kong
Victoria Kong
JMJake Moscarelli
Jake Moscarelli
MAMichael Alperovich
Michael Alperovich
Background: This study examines temporal trends in otoplasty volume and inflation-adjusted cost, and characterizes variation by patient age, sex, anesthesia type, insurance, and geographic region using a national pediatric hospital database. Methods: Retrospective cohort analysis of the Pediatric Health Information System (PHIS) database. Patients undergoing otoplasty (CPT 69300) from 2000 to 2025 were identified. Patients with congenital ear malformations other than a prominent ear (ICD-10 Q17.5) were excluded. Annual procedure volume and inflation-adjusted estimated costs were modeled with ordinary least-squares regression. Differences in cost across anesthesia type, insurance category, and census region were assessed with Kruskal-Wallis and Wilcoxon pairwise tests. Results: A total of 3428 patients underwent otoplasty (51.7% male). Annual volume increased significantly (β=3.7 procedures/year, R 2 =0.57, P <0.001). Inflation-adjusted median cost rose by $161/year ( R 2 =0.67, P <0.001). Median age at surgery was 8.0 years (IQR: 6–12). General anesthesia was associated with higher costs than local anesthesia ($6930 versus $5355; P <0.001). Costs were highest in the West ($7136) and lowest in the South ($4793; P <0.001). Medicaid/CHIP patients incurred higher median costs than privately insured patients ($7188 versus $6496; P =0.010). Conclusions: Otoplasty utilization and real costs have increased significantly at U.S. children’s hospitals over the past 2 decades. Meaningful variation exists by anesthesia type, payer, and geography. These findings highlight opportunities to standardize care delivery and address cost disparities in pediatric otoplasty.